Browse by category

First patients randomised in KaiNETIC Global Phase 3 Clinical Program of ribupatide

Kailera Therapeutics has announced the randomisation of the first participants in the KaiNETIC global Phase 3 clinical program of ribupatide (also known as KAI-9531), an investigational once-weekly injectable dual GLP-1/GIP receptor agonist peptide, for the treatment of people living with obesity or overweight. The KaiNETIC global Phase 3 clinical program includes three global, double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3

First patients randomised in KaiNETIC Global Phase 3 Clinical Program of ribupatide

5 hours ago

Viking’s dual GLP-1/GIP Receptor Agonist VK2735 shows 14.7% reduction in mean body weight from baseline at 13 weeks

2 days ago

Weight loss drugs and surgery improve fat-to-muscle ratio in obesity

3 days ago

Browse by category

First patients randomised in KaiNETIC Global Phase 3 Clinical Program of ribupatide

Browse by tag

First patients randomised in KaiNETIC Global Phase 3 Clinical Program of ribupatide

Viking’s dual GLP-1/GIP Receptor Agonist VK2735 shows 14.7% reduction in mean body weight from baseline at 13 weeks

Weight loss drugs and surgery improve fat-to-muscle ratio in obesity

Back to Top